(Incorporated in Australia)

We are a genomics-based company with a mission dedicated to empowering families to have healthy children by providing in-vitro fertilization (“IVF”) patients and providers unparalleled insights into an embryo’s genetic disease. Our flagship test Panacea-GenomeScreen™ offers preimplantation genetic testing (“PGT”) via whole genome sequencing (“WGS”) of individuals, couples and IVF embryos. Through our test, which we intend to launch commercially in the third quarter of the fiscal year ended June 30, 2025, IVF clinics can gain an actionable genome report screen for over 3,200 severe and fatal genetic diseases, enabling deeper understanding and greater confidence by clinicians and patients undertaking fertility treatments. The test will utilize our proprietary genome analysis algorithms, and are embedded within the platform to prioritize and generate reports. Prospective parents will be able to access the information provided through PGT-WGS reports provided through our proprietary artificial intelligence platform to choose the healthiest start for future generations.

Panacea-GenomeScreen™ is the first standalone test in the high prominence PGT market which accounts for ethnic and geographic diversity, and detects both fertility-fraud (unauthorized substitution or misuse of reproductive materials) and consanguinity (genetic relatedness between prospective parents). Panacea-GenomeScreen™ is a powerful tool for identifying de novo mutations in embryos, anywhere in the genome, before implantation. By screening for these mutations, prospective parents can make informed decisions about their reproductive options and reduce the risk of having a child with a genetic disorder.

De novo mutations, which are new genetic changes not inherited from either parent, occur at random positions in any given person’s DNA, with everyone carrying about 70 de novo mutations in their genome. They cause a significant genetic disease in 1 in every 25 pregnancies and 80% of all individuals with severe developmental disorders have causative de novo mutations. In contrast, inherited mutations which are passed down from parents to their children and detected by both Panacea-GenomeScreen™ or preconception carrier screening, affect about 1 in 300 pregnancies.¹ Given that de novo mutations account for a significant portion of genetic disorders, the ability to detect these changes through advanced genetic tests like Panacea-GenomeScreen™ is crucial. By identifying embryos with de novo mutations, couples undergoing IVF can select embryos with the lowest risk of developing genetic disorders, increasing the chances of a healthy pregnancy and baby.

We intend to focus on commencing our business in the United States in the third quarter of the fiscal year ended June 30, 2025.

Note: Net loss and revenue are for the year that ended June 30, 2024.

(Note: GenEmbryonics Limited filed its F-1 on Feb. 20, 2025, and disclosed the terms for its micro-cap IPO: The company is offering 1.1 million shares (1,095,000 shares) at $4.75 each – the assumed IPO price – to raise $5.2 million.)